Sera Prognostics, Inc. (SERA)
Largest Insider Buys in Sector
SERA Stock Price History Chart
SERA Stock Performance
About Sera Prognostics, Inc.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The …
Insider Activity of Sera Prognostics, Inc.
Over the last 12 months, insiders at Sera Prognostics, Inc. have bought $0 and sold $3.82M worth of Sera Prognostics, Inc. stock.
On average, over the past 5 years, insiders at Sera Prognostics, Inc. have bought $9,600 and sold $1.34M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,000 shares for transaction amount of $9,600 was made by Jackson Benjamin (General Counsel) on 2022‑06‑14.
List of Insider Buy and Sell Transactions, Sera Prognostics, Inc.
| 2024-12-10 | Sale | Chief Executive Officer | 26,224 0.0726% | $7.41 | $194,320 | +4.62% | ||
| 2024-12-10 | Sale | Chief Financial Officer | 5,730 0.0159% | $7.41 | $42,459 | +4.62% | ||
| 2024-12-06 | Sale | director | 93 0.0003% | $7.12 | $662 | +16.19% | ||
| 2024-11-11 | Sale | Chief Executive Officer | 12,075 0.0365% | $7.32 | $88,389 | -4.50% | ||
| 2024-11-11 | Sale | Chief Financial Officer | 7,179 0.0217% | $7.32 | $52,550 | -4.50% | ||
| 2024-11-11 | Sale | Chief Data Officer | 4,078 0.0123% | $7.32 | $29,851 | -4.50% | ||
| 2024-11-11 | Sale | General Counsel | 4,727 0.0143% | $7.32 | $34,602 | -4.50% | ||
| 2024-11-11 | Sale | Chief Information Officer | 4,727 0.0143% | $7.32 | $34,602 | -4.50% | ||
| 2024-11-11 | Sale | Chief Scientific Officer | 4,727 0.0143% | $7.32 | $34,602 | -4.50% | ||
| 2024-11-11 | Sale | director | 95 0.0003% | $7.32 | $695 | -4.50% | ||
| 2024-10-07 | Sale | director | 96 0.0003% | $7.15 | $686 | +5.78% | ||
| 2024-09-10 | Sale | Chief Executive Officer | 25,085 0.0792% | $7.57 | $189,893 | -0.07% | ||
| 2024-09-10 | Sale | Chief Financial Officer | 5,056 0.016% | $7.57 | $38,274 | -0.07% | ||
| 2024-09-06 | Sale | director | 96 0.0003% | $7.16 | $687 | +2.00% | ||
| 2024-08-07 | Sale | Chief Executive Officer | 12,327 0.039% | $7.42 | $91,466 | -0.68% | ||
| 2024-08-07 | Sale | Chief Financial Officer | 6,760 0.0214% | $7.42 | $50,159 | -0.68% | ||
| 2024-08-07 | Sale | Chief Data Officer | 4,333 0.0137% | $7.42 | $32,151 | -0.68% | ||
| 2024-08-07 | Sale | General Counsel | 5,022 0.0159% | $7.42 | $37,263 | -0.68% | ||
| 2024-08-07 | Sale | Chief Information Officer | 5,022 0.0159% | $7.42 | $37,263 | -0.68% | ||
| 2024-08-07 | Sale | Chief Scientific Officer | 5,022 0.0159% | $7.42 | $37,263 | -0.68% |
Insider Historical Profitability
| Jackson Benjamin | General Counsel | 135528 0.4131% | $7.95 | 1 | 6 | +51.59% |
Institutional Investor Ownership
| Baker Bros Advisors LP | $49.45M | 16.64 | 5.43M | 0% | +$0 | 0.36 | |
| RA Capital Management, L.P. | $18.42M | 6.2 | 2.02M | New | +$18.42M | 0.02 | |
| Vivo Capital | $15.02M | 5.05 | 1.65M | 0% | +$0 | 1.31 | |
| The Vanguard Group | $8.16M | 2.74 | 896,163 | -1.47% | -$121,384.90 | <0.0001 | |
| Invesco | $5.66M | 1.9 | 621,834 | New | +$5.66M | <0.01 |